Emory University Lung Cancer SPORE

埃默里大学肺癌孢子

• 批准号: 10685410
• 负责人: HAIAN FU
• 金额: $ 183.99万
• 依托单位: EMORY UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2019
• 资助国家: 美国
• 起止时间: 2019-07-10 至 2024-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10685410
• 关键词: ABCG2 gene; Address; Animal Cancer Model; Animal Model; Area; Award; Biological Markers; Biometry; CD8-Positive T-Lymphocytes; Cancer Etiology; Cancer Patient; Cell Fate Control; Cessation of life; Collaborations; Comprehensive Cancer Center; Coupled; Data; Dedications; Dependence; Deuterium; Development; Diagnosis; Disease; Drug resistance; Epidermal Growth Factor Receptor; Funding; Goals; Health Sciences; Healthcare Systems; Hematology; Human; Immune checkpoint inhibitor; Immunologic Factors; Immunologist; Immunotherapy; In Vitro; Institution; Investigation; Ionizing radiation; Journals; KRAS2 gene; Label; Location; MERTK gene; Malignant Neoplasms; Malignant neoplasm of lung; Mediator; Medical Oncology; Modernization; Molecular; Molecular Target; Mutate; Mutation; Neoadjuvant Therapy; Non-Small-Cell Lung Carcinoma; Oncologist; Outcome; PD-1 blockade; Pathology; Patient-Focused Outcomes; Patients; Phenotype; Phosphorylation; Phosphorylation Site; Play; Prognostic Marker; Property; Publishing; Radiation therapy; Recommendation; Reproduction spores; Research; Research Personnel; Resistance; Resource Sharing; Role; SDZ RAD; Safety; Scientist; Signal Transduction; Site; T-Lymphocyte; TP53 gene; Technology; Testing; Therapeutic Agents; Therapy trial; Treatment Efficacy; Tumor Immunity; Universities; Work; anti-PD1 therapy; anti-cancer; anticancer research; antitumor effect; biomedical informatics; cancer therapy; career; clinical application; clinical efficacy; clinical investigation; drug discovery; experience; improved; improved outcome; in vivo; inhibitor; innovation; lung cancer cell; mTOR inhibition; medical schools; member; molecular targeted therapies; mortality; multidisciplinary; mutant; novel; novel strategies; novel therapeutic intervention; patient population; phase 1 study; preclinical development; programmed cell death protein 1; programs; radiation resistance; resistance mechanism; small molecule; stem; stem-like cell; targeted agent; targeted treatment; therapeutic target; therapy resistant; translational goal; translational scientist; tumor; tumorigenesis

OVERVIEW SUMMARY/ABSTRACT Lung cancer is the leading cause of cancer-related deaths, with more than 1.6 million deaths/year globally. It is often diagnosed at an advanced stage and is associated with poor outcomes for the majority of patients. This application for a lung cancer SPORE award from Emory University brings together an outstanding and multi- disciplinary team of oncologists, immunologists, drug discovery experts, and translational researchers dedicated to lung cancer research to address critical questions that will improve the outcome for patients with this lethal disease. Our proposed program will have significant impact in two crucial areas of lung cancer management: enhancing the efficacy of immunotherapy and overcoming treatment resistance through the development of novel molecularly targeted agents. Through strong teamwork carried out by this highly collaborative team of dedicated investigators, and building on exciting data published in leading journals by our group since our previous SPORE application, this revised submission aims to achieve substantial improvements in the management of patients with non-small cell lung cancer (NSCLC), through three overall Specific Aims: Aim 1: To evaluate stem-like T cells and improve efficacy of checkpoint inhibitors in NSCLC (Project 1); Aim 2: To target MERTK to improve outcomes for EGFR-mutated NSCLC (Project 2); and Aim 3: To target Bax signaling to overcome treatment resistance in NSCLC (Project 3). The Emory Lung Cancer SPORE program will be supported by close interaction with the Administrative Core (Core 1), Pathology Core (Core 2) and the Biostatistics and Biomedical Informatics Core (Core 3), and will conduct Career Enhancement and Developmental Research Programs (CEP and DRP). The SPORE program will benefit from regular advice and recommendations from External and Internal Advisory Board members regarding its progress and direction. Our program will receive strong institutional support including modern research space, excellent shared resources, and a significant level of matching funds (totaling $2.25M) from the Winship Cancer Institute of Emory University (an NCI-designated Comprehensive Cancer Center), Emory University Woodruff Health Sciences Center, Emory Healthcare System, Emory School of Medicine, and the Department of Hematology and Medical Oncology. Through team-driven innovative research efforts in immunotherapies and molecularly targeted therapeutics, we are confident that this SPORE program, in collaboration with other lung cancer SPORE sites, will have a major positive impact on the management of lung cancer.

概述/摘要 肺癌是癌症相关死亡的主要原因，全球每年有超过160万例死亡。是 通常在晚期被诊断出，并且与大多数患者的不良结果相关。这 埃默里大学肺癌SPORE奖的申请汇集了一个杰出的和多- 由肿瘤学家、免疫学家、药物发现专家和翻译研究人员组成的学科团队致力于 肺癌研究，以解决关键问题，将改善这种致命的患者的结果 疾病我们提出的计划将在肺癌管理的两个关键领域产生重大影响： 提高免疫疗法的疗效，并通过开发 新型分子靶向药物。通过这个高度协作的团队进行的强有力的团队合作， 专门的研究人员，并建立在令人兴奋的数据发表在领先的期刊上，由我们的小组，因为我们的 之前的SPORE应用程序，本次修订提交的目的是实现实质性的改善， 通过三个总体目标管理非小细胞肺癌（NSCLC）患者具体目标：目标1： 评估干细胞样T细胞并提高NSCLC中检查点抑制剂的疗效（项目1）;目的2： 靶向MERTK以改善EGFR突变NSCLC的结局（项目2）;目标3：靶向Bax 信号转导以克服NSCLC中的治疗耐药性（项目3）。埃默里肺癌孢子计划 将通过与行政核心（核心1）、病理核心（核心2）和 生物统计学和生物医学信息学核心（核心3），并将进行职业提升和 发展研究计划（CEP和DRP）。SPORE计划将受益于定期咨询， 外部和内部咨询委员会成员就其进展和方向提出的建议。我们 该计划将获得强大的机构支持，包括现代研究空间，优秀的共享资源， 以及埃默里大学温希普癌症研究所提供的大量配套资金（总计225万美元） (an NCI-designated Comprehensive Cancer Center），埃默里大学伍德拉夫健康科学中心，埃默里 医疗保健系统，埃默里医学院，血液学和肿瘤内科。 通过在免疫疗法和分子靶向疗法方面的团队驱动的创新研究工作，我们 我们相信，这个SPORE计划，与其他肺癌SPORE网站合作，将有一个重大的 对肺癌的治疗有积极的影响。

项目成果

Targeting MERTK and AXL in EGFR Mutant Non-Small Cell Lung Cancer.

• DOI: 10.3390/cancers13225639
• 发表时间: 2021-11-11
• 期刊: Cancers
• 影响因子: 5.2
• 作者: Yan D;Earp HS;DeRyckere D;Graham DK
• 通讯作者: Graham DK

Hope and Challenges: Immunotherapy in EGFR-Mutant NSCLC Patients.

• DOI: 10.3390/biomedicines11112916
• 发表时间: 2023-10-28
• 期刊: Biomedicines
• 影响因子: 4.7

TMPRSS2 and SARS-CoV-2 SPIKE interaction assay for uHTS.

• DOI: 10.1093/jmcb/mjad017
• 发表时间: 2023-08-03
• 期刊: Journal of molecular cell biology
• 影响因子: 5.5

Spatially variant immune infiltration scoring in human cancer tissues.

• DOI: 10.1038/s41698-022-00305-4
• 发表时间: 2022-09-01
• 期刊: NPJ PRECISION ONCOLOGY
• 影响因子: 7.9
• 作者: Allam, Mayar;Hu, Thomas;Lee, Jeongjin;Aldrich, Jeffrey;Badve, Sunil S.;Gokmen-Polar, Yesim;Bhave, Manali;Ramalingam, Suresh S.;Schneider, Frank;Coskun, Ahmet F.
• 通讯作者: Coskun, Ahmet F.

Multiplexed protein profiling reveals spatial subcellular signaling networks.

• DOI: 10.1016/j.isci.2022.104980
• 发表时间: 2022-09-16
• 期刊: ISCIENCE
• 影响因子: 5.8
• 作者: Cai, Shuangyi;Hu, Thomas;Venkatesan, Mythreye;Allam, Mayar;Schneider, Frank;Ramalingam, Suresh S.;Sun, Shi-Yong;Coskun, Ahmet F.
• 通讯作者: Coskun, Ahmet F.